NCT03065062
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes: Patients that have tumor with suspected PI3K-pathway dependence will be eligible for Part II of the study
Exclusions: Participants with symptomatic brain metastases that require active treatment
https://ClinicalTrials.gov/show/NCT03065062